他汀类药物自从问世以来,凭借强大的调脂能力与优越的预防心血管事件作用,已得到普遍认可和广泛应用。他汀的安全性与耐受性也经受了实践的检验。然而,2001年西立伐他汀因导致肌溶解相关死亡撤出市场的事件重新引发了对于他汀安全性的关注。他汀相关性肌病更是成为近年来研究他汀的热点之一。 1 他汀相关性肌病发生率他汀相关性肌病包括从普通的肌肉症状,如肌无力,肌痛,肌痉挛到严重的横纹肌溶解症,可伴有肌酸磷酸肌酶 (CK)升高。总体上,他汀相关性肌病发生率是相当低的。临床试验表明,他汀治疗出现任何肌肉症状者约5％,与安 Since the advent of statins, with its strong ability to regulate lipid and superior cardiovascular disease prevention, has been widely recognized and widely used. The safety and tolerability of statins have also stood the test of practice. However, the withdrawal of cerivastatin from the market leading to myolysis in 2001 revived concerns about the safety of statins. Statin-related myopathy is one of the hot spots in the study of statins in recent years. 1 statin-related myopathy incidence of statin-related myopathy, including common muscle symptoms, such as muscle weakness, muscle pain, muscle spasms to severe rhabdomyolysis, may be associated with creatine phosphokinase (CK) increased. In general, the incidence of statin-related myopathy is quite low. Clinical trials have shown that statins treat about 5% of any muscle symptoms and are safe